GlassScriptPhysician profile
Christy S Walls
NPI 1942976238
$3,590.69
in general payments reported to CMS, 2019-2025
23 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $1,154 · 2024: $733 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,327 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,326.59 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $821.36 | 2024-2025 | Aquabeam System |
| Pfizer INC. | $337.13 | 2022-2025 | |
| Teleflex LLC | $290.60 | 2023-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $264.86 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Medtronic, INC. | $261.93 | 2025 | Interstim |
| Coloplast Corp | $191.53 | 2022-2024 | Titan |
| Bayer Healthcare Pharmaceuticals INC. | $173.19 | 2023 | |
| Merck Sharp & Dohme LLC | $169.81 | 2023 | Keytruda, Lynparza, Welireg |
| Dentsply Ih Ab | $163.37 | 2025 | Lofric |
| Sumitomo Pharma America, INC. | $160.67 | 2023-2024 | Orgovyx |
| Endo USA, INC. | $128.18 | 2024 | Xiaflex |
| Endo Pharmaceuticals INC. | $110.76 | 2022-2023 | Xiaflex, Aveed, Edex |
| Calyxo, INC. | $101.47 | 2025 | Cvac Aspiration System |
| Seagen INC. | $84.99 | 2025 | |
| Urogen Pharma, INC. | $71.29 | 2023-2024 | Jelmyto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66.07 | 2023 | |
| Halozyme INC | $39.80 | 2023 | |
| Myriad Genetic Laboratories, INC. | $35.98 | 2025 | Prolaris |
| 180 Medical, INC. | $28.98 | 2023 | Gentlecath |
| Astellas Pharma US INC | $27.50 | 2023 | Myrbetriq |
| Accord Healthcare, INC. | $23.93 | 2023 | |
| Tolmar, INC. | $19.31 | 2024 | |
| Convatec INC. | $17.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Walls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.